ABSTRACT

In this study; we aimed to determine the identification of yeasts from the samples of the patients that come from different clinics and also we aimed to perform the antifungal susceptibility testing of yeasts.

Antifungal susceptibility test results of yeasts that were isolated from 69 samples of the patients that come from different clinics to our microbiology laboratory during the period January 2012 and December 2012 were evaluated. The yeasts identified by germ tube test, cornmeal tween 80 and VITEC 2 Compact (Biomerieux, France) yeast identification system. The antifungal susceptibility tests were performed for amphotericin B, flucytosine, fluconazole and voriconazole by using VITEC 2 Compact system.

In this study yeast was isolated from totally 69 clinical samples; 37 from wound, 23 from urine, 5 from blood and 4 from sputum. Among these isolates; 49 (% 71) of the yeasts were determined as C.albicans which was the most common yeast followed by; 6 C.tropicalis (% 8.7), 6 C.glabrata (% 8.7), 5 C.parapsilosis (% 7.3), 2 C.dubliniensis (% 2.9), and 1 C.guilliermondi (% 1.4). According to the results of antifungal susceptibility tests; no resistance was detected against flucytosine. Resistance for voriconazole was detected in 2 C.glabrata isolates (% 10) and 1 C. parapsilosis isolate (% 5).The resistance for fluconazole was detected in 2 C.albicans isolates (% 4),1 C.glabrata isolate (% 5) and 1 C.tropicalis isolate (% 5). Additionally, in 2 C.glabrata (% 10), 1 C.parapisilosis (% 5) and 1 C.dubliniensis (% 5) isolates resistant to amphotericin B was detected.

In conclusion; risk for candida infections is in increasing trend parallel with continuous increase in the patient population. Therefore; we concluded that, epidemiological studies for the identification of candida species and antifungal susceptibility testing of new antifungal agents must be done.